## Board Diversity Matrix for Acurx Pharmaceuticals, Inc.

As of December 12, 2023

|  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Total Number of Directors | 7 |  |  |  |  |
| Part I: Gender Identity | Female | Male | Non-Binary | Did Not <br> Disclose <br> Gender |  |
| Directors | 0 | 7 | 0 | 0 |  |

Part II: Demographic Background

| African American or Black | 0 | 0 | 0 | 0 |
| :--- | :---: | :---: | :---: | :---: |
| Alaskan Native or American Indian | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Hispanic or Latinx | 0 | 0 | 0 | 0 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| Two or More Races or Ethnicities | 0 | 0 |  |  |
| LGBTQ+ | 0 |  |  |  |
| Did Not Disclose Demographic Background |  | 0 |  |  |

## Explanation

As a Smaller Reporting Company listed on the Nasdaq Capital Market tier, Acurx Pharmaceuticals, Inc. (the "Company") is subject to Nasdaq Rule $5605(\mathrm{f})(2)(\mathrm{C})$, which requires the Company to have, or explain why it does not have, at least two Diverse directors, including at least one director who self-identifies as Female. Under Rule $5605(f)(7)$, the Company is required to have at least one Diverse director by December 31, 2023, and a second Diverse director by December 31, 2026. The Company has chosen to satisfy Rule $5605(\mathrm{f})(2)(\mathrm{C})$ by explaining its reasons for not meeting the diversity objectives of Rule $5605(\mathrm{f})(2)(\mathrm{C})$, which the Company has set forth below.

The Company has not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, however, in identifying and evaluating nominees for director, the board of directors of the Company considers diversity of educational background, diversity of professional experience, knowledge of the Company's business, integrity, professional reputation, independence, wisdom and the ability to represent the best interests of the Company's stockholders.

